Abstract
Cell death, particularly that of tubule epithelial cells, contributes critically to the pathophysiology of kidney disease. A body of evidence accumulated over the past 15 years has ascribed a central pathophysiological role to a particular form of regulated necrosis, termed necroptosis, to acute tubular necrosis, nephron loss and maladaptive renal fibrogenesis. Unlike apoptosis, which is a non-immunogenic process, necroptosis results in the release of cellular contents and cytokines, which triggers an inflammatory response in neighbouring tissue. This necroinflammatory environment can lead to severe organ dysfunction and cause lasting tissue injury in the kidney. Despite evidence of a link between necroptosis and various kidney diseases, there are no available therapeutic options to target this process. Greater understanding of the molecular mechanisms, triggers and regulators of necroptosis in acute and chronic kidney diseases may identify shortcomings in current approaches to therapeutically target necroptosis regulators and lead to the development of innovative therapeutic approaches.
Key points
-
Necroptosis is a form of programmed cell death that leads to cell lysis and an inflammatory response in neighbouring tissues; dysregulation of the pathway is widely implicated in kidney diseases.
-
The core regulators of the necroptosis pathway are the kinases, RIPK1 and RIPK3, and the executioner pseudokinase, MLKL; each of these proteins is regulated by diverse interactions and modifications.
-
Most experimental studies of necroptosis in kidney diseases have been performed in rodent models of disease; further studies are therefore essential to define the contribution of this cell death mode to human kidney diseases.
-
RIPK1 inhibitors are currently being explored in clinical trials to treat neuronal and inflammatory diseases, but so far, the results have not been convincing; future trials are required to establish the viability of targeting necroptosis in kidney diseases.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Müller, T. et al. Necroptosis and ferroptosis are alternative cell death pathways that operate in acute kidney failure. Cell. Mol. Life Sci. 74, 3631–3645 (2017).
Bedoui, S., Herold, M. J. & Strasser, A. Emerging connectivity of programmed cell death pathways and its physiological implications. Nat. Rev. Mol. Cell Biol. 21, 678–695 (2020).
Choi, M. E., Price, D. R., Ryter, S. W. & Choi, A. M. K. Necroptosis: a crucial pathogenic mediator of human disease. J. Clin. Invest. Insight 4, e128834 (2019).
Kearney, C. J. & Martin, S. J. An inflammatory perspective on necroptosis. Mol. Cell 65, 965–973 (2017).
Holler, N. et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 1, 489–495 (2000).
Degterev, A. et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 1, 112–119 (2005).
Cho, Y. S. et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 137, 1112–1123 (2009).
He, S. et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-α. Cell 137, 1100–1111 (2009).
Zhang, D. W. et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 325, 332–336 (2009).
Sun, L. et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148, 213–227 (2012).
Zhao, J. et al. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc. Natl Acad. Sci. USA 109, 5322–5327 (2012).
Mompeán, M. et al. The structure of the necrosome RIPK1-RIPK3 core, a human hetero-amyloid signaling complex. Cell 173, 1244–1253.e10 (2018).
Chen, X. et al. Mosaic composition of RIP1-RIP3 signalling hub and its role in regulating cell death. Nat. Cell Biol. 24, 471–482 (2022).
Murphy, J. M. et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 39, 443–453 (2013).
Sethi, A. et al. Membrane permeabilization is mediated by distinct epitopes in mouse and human orthologs of the necroptosis effector, MLKL. Cell Death Differ. 29, 1804–1815 (2022).
Pasparakis, M. & Vandenabeele, P. Necroptosis and its role in inflammation. Nature 517, 311–320 (2015).
Yuan, F. et al. Z-DNA binding protein 1 promotes heatstroke-induced cell death. Science 376, 609–615 (2022).
Zhang, W., Fan, W., Guo, J. & Wang, X. Osmotic stress activates RIPK3/MLKL-mediated necroptosis by increasing cytosolic pH through a plasma membrane Na+/H+ exchanger. Sci. Signal. 15, eabn5881 (2022).
Zhang, T. et al. Influenza virus Z-RNAs induce ZBP1-mediated necroptosis. Cell 180, 1115–1129.e13 (2020).
Chan, F. K., Luz, N. F. & Moriwaki, K. Programmed necrosis in the cross talk of cell death and inflammation. Annu. Rev. Immunol. 33, 79–106 (2015).
Meng, Y. et al. Human RIPK3 maintains MLKL in an inactive conformation prior to cell death by necroptosis. Nat. Commun. 12, 6783 (2021).
Samson, A. L. et al. MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis. Nat. Commun. 11, 3151 (2020).
Duprez, L. et al. RIP Kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity 35, 908–918 (2011).
Meng, Y., Sandow, J. J., Czabotar, P. E. & Murphy, J. M. The regulation of necroptosis by post-translational modifications. Cell Death Differ. 28, 861–883 (2021).
Weinlich, R. & Green, D. R. The two faces of receptor interacting protein kinase-1. Mol. Cell 56, 469–480 (2014).
Chen, W. et al. Diverse sequence determinants control human and mouse receptor interacting protein 3 (RIP3) and mixed lineage kinase domain-like (MLKL) interaction in necroptotic signaling. J. Biol. Chem. 288, 16247–16261 (2013).
Meng, Y. et al. Human RIPK3 C-lobe phosphorylation is essential for necroptotic signaling. Cell Death Dis. 13, 565 (2022).
Samson, A. L. et al. A toolbox for imaging RIPK1, RIPK3, and MLKL in mouse and human cells. Cell Death Differ. 28, 2126–2144 (2021).
Jaco, I. et al. MK2 phosphorylates RIPK1 to prevent TNF-induced cell death. Mol. Cell 66, 698–710 (2017).
Dondelinger, Y. et al. MK2 phosphorylation of RIPK1 regulates TNF-mediated cell death. Nat. Cell Biol. 19, 1237–1247 (2017).
Roedig, J. et al. USP22 controls necroptosis by regulating receptor-interacting protein kinase 3 ubiquitination. EMBO Rep. 22, e50163 (2021).
Garcia, L. R. et al. Ubiquitylation of MLKL at lysine 219 positively regulates necroptosis-induced tissue injury and pathogen clearance. Nat. Commun. 12, 3364 (2021).
Yoon, S., Kovalenko, A., Bogdanov, K. & Wallach, D. MLKL, the protein that mediates necroptosis, also regulates endosomal trafficking and extracellular vesicle generation. Immunity 47, 51–65 (2017).
Liu, Z. et al. Oligomerization-driven MLKL ubiquitylation antagonizes necroptosis. EMBO J. 40, e103718 (2021).
Yoon, S., Bogdanov, K. & Wallach, D. Site-specific ubiquitination of MLKL targets it to endosomes and targets Listeria and Yersinia to the lysosomes. Cell Death Differ. 29, 306–322 (2022).
Geserick, P. et al. Absence of RIPK3 predicts necroptosis resistance in malignant melanoma. Cell Death Dis. 6, e1884 (2015).
Preston, S. P. et al. Epigenetic silencing of RIPK3 in hepatocytes prevents MLKL-mediated necroptosis from contributing to liver pathologies. Gastroenterology 163, 1643–1657 (2022).
Broz, P., Pelegrín, P. & Shao, F. The gasdermins, a protein family executing cell death and inflammation. Nat. Rev. Immunol. 20, 143–157 (2020).
Sarhan, M. et al. Immunological consequences of kidney cell death. Cell Death Dis. 9, 114 (2018).
Mahdi, L. K. et al. Discovery of a family of mixed lineage kinase domain-like proteins in plants and their role in innate immune signaling. Cell Host Microbe 28, 813–824.e6 (2020).
Nailwal, H. & Chan, F. K. Necroptosis in anti-viral inflammation. Cell Death Differ. 26, 4–13 (2019).
Kearney, C. J. et al. Necroptosis suppresses inflammation via termination of TNF- or LPS-induced cytokine and chemokine production. Cell Death Differ. 22, 1313–1327 (2015).
Liu, Z. et al. A class of viral inducer of degradation of the necroptosis adaptor RIPK3 regulates virus-induced inflammation. Immunity 54, 247–258.e7 (2021).
Petrie, E. J. et al. Viral MLKL homologs subvert necroptotic cell death by sequestering cellular RIPK3. Cell Rep. 28, 3309–3319.e5 (2019).
Pearson, J. S. et al. EspL is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis and inflammation. Nat. Microbiol. 2, 16258 (2017).
Khwaja, A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin. Pract. 120, c179–c184 (2012).
Pefanis, A., Ierino, F. L., Murphy, J. M. & Cowan, P. J. Regulated necrosis in kidney ischemia-reperfusion injury. Kidney Int. 96, 291–301 (2019).
Wu, M. Y. et al. Current mechanistic concepts in ischemia and reperfusion injury. Cell. Physiol. Biochem. 46, 1650–1667 (2018).
Linkermann, A., Stockwell, B. R., Krautwald, S. & Anders, H. J. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat. Rev. Immunol. 14, 759–767 (2014).
Linkermann, A. et al. Rip1 (Receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury. Kidney Int. 81, 751–761 (2012).
von Samson-Himmelstjerna, F. A. et al. Progress and setbacks in translating a decade of ferroptosis research into clinical practice. Cells 11, 2134 (2022).
Linkermann, A. et al. Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc. Natl Acad. Sci. USA 110, 12024–12029 (2013).
Newton, K. et al. RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury. Cell Death Differ. 23, 1565–1576 (2016).
Martin-Sanchez, D. et al. Bone marrow-derived RIPK3 mediates kidney inflammation in acute kidney injury. J. Am. Soc. Nephrol. 33, 357–373 (2022).
Linkermann, A. et al. Synchronized renal tubular cell death involves ferroptosis. Proc. Natl Acad. Sci. USA 111, 16836–16841 (2014).
Moerke, C., Bleibaum, F., Kunzendorf, U. & Krautwald, S. Combined knockout of RIPK3 and MLKL reveals unexpected outcome in tissue injury and inflammation. Front. Cell Dev. Biol. 7, 19 (2019).
Naito, M. G. et al. Sequential activation of necroptosis and apoptosis cooperates to mediate vascular and neural pathology in stroke. Proc. Natl Acad. Sci. USA 117, 4959–4970 (2020).
Balzer, M. S. et al. Single-cell analysis highlights differences in druggable pathways underlying adaptive or fibrotic kidney regeneration. Nat. Commun. 13, 4018 (2022).
Moerke, C. et al. The anticonvulsive Phenhydan® suppresses extrinsic cell death. Cell Death Differ. 26, 1631–1645 (2019).
Riebeling, T. et al. Primidone blocks RIPK1-driven cell death and inflammation. Cell Death Differ. 28, 1610–1626 (2021).
Gong, Y. N. et al. ESCRT-III acts downstream of MLKL to regulate necroptotic cell death and its consequences. Cell 169, 286–300 (2017).
von Mässenhausen, A. et al. Phenytoin inhibits necroptosis. Cell Death Dis. 9, 359 (2018).
Poston, J. T. & Koyner, J. L. Sepsis associated acute kidney injury. BMJ 364, k4891 (2019).
Birkelo, B. C., Pannu, N. & Siew, E. D. Overview of diagnostic criteria and epidemiology of acute kidney injury and acute kidney disease in the critically ill patient. Clin. J. Am. Soc. Nephrol. 17, 717–735 (2022).
Peerapornratana, S., Manrique-Caballero, C. L., Gómez, H. & Kellum, J. A. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int. 96, 1083–1099 (2019).
Zelic, M. et al. RIP kinase 1-dependent endothelial necroptosis underlies systemic inflammatory response syndrome. J. Clin. Invest. 128, 2064–2075 (2018).
Laurien, L. et al. Autophosphorylation at serine 166 regulates RIP kinase 1-mediated cell death and inflammation. Nat. Commun. 11, 1747 (2020).
Sharma, A. et al. Receptor-interacting protein kinase 3 deficiency inhibits immune cell infiltration and attenuates organ injury in sepsis. Crit. Care 18, R142 (2014).
Chen, H. et al. RIPK3 collaborates with GSDMD to drive tissue injury in lethal polymicrobial sepsis. Cell Death Differ. 27, 2568–2585 (2020).
Sureshbabu, A. et al. RIPK3 promotes sepsis-induced acute kidney injury via mitochondrial dysfunction. J. Clin. Invest. Insight 3, e98411 (2018).
Qiu, P. et al. Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis. Crit. Care Med. 41, 2419–2429 (2013).
Dejager, L., Pinheiro, I., Dejonckheere, E. & Libert, C. Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? Trends Microbiol. 19, 198–208 (2011).
Shashaty, M. G. et al. Plasma levels of receptor interacting protein kinase-3 (RIP3), an essential mediator of necroptosis, are associated with acute kidney injury in critically ill trauma patients. Shock 46, 139–143 (2016).
Shashaty, M. G. S. et al. Plasma receptor interacting protein kinase-3 levels are associated with acute respiratory distress syndrome in sepsis and trauma: a cohort study. Crit. Care 23, 235 (2019).
Yu, X. et al. A cytosolic heat shock protein 90 and co-chaperone p23 complex activates RIPK3/MLKL during necroptosis of endothelial cells in acute respiratory distress syndrome. J. Mol. Med. 98, 569–583 (2020).
Mulay, S. R. & Anders, H. J. Crystal nephropathies: mechanisms of crystal-induced kidney injury. Nat. Rev. Nephrol. 13, 226–240 (2017).
Mulay, S. R. et al. Cytotoxicity of crystals involves RIPK3-MLKL-mediated necroptosis. Nat. Commun. 7, 10274 (2016).
Desai, J. et al. PMA and crystal-induced neutrophil extracellular trap formation involves RIPK1-RIPK3-MLKL signaling. Eur. J. Immunol. 46, 223–229 (2016).
Desai, J. et al. Particles of different sizes and shapes induce neutrophil necroptosis followed by the release of neutrophil extracellular trap-like chromatin. Sci. Rep. 7, 15003 (2017).
Liu, W. et al. RGMb protects against acute kidney injury by inhibiting tubular cell necroptosis via an MLKL-dependent mechanism. Proc. Natl Acad. Sci. USA 115, E1475–E1484 (2018).
Mulay, S. R. et al. Mitochondria permeability transition versus necroptosis in oxalate-induced AKI. J. Am. Soc. Nephrol. 30, 1857–1869 (2019).
Prajapati, S. et al. 6,7-Dihydroxycoumarin ameliorates crystal-induced necroptosis during crystal nephropathies by inhibiting MLKL phosphorylation. Life Sci. 271, 119193 (2021).
Shi, C. et al. Crystal clots as therapeutic target in cholesterol crystal embolism. Circ. Res. 126, e37–e52 (2020).
Kronzon, I. & Saric, M. Cholesterol embolization syndrome. Circulation 122, 631–641 (2010).
Mulay, S. R. & Anders, H. J. Crystallopathies. N. Engl. J. Med. 374, 2465–2476 (2016).
Klück, V. et al. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatol. 2, e270–e280 (2020).
Perazella, M. A. & Izzedine, H. New drug toxicities in the onco-nephrology world. Kidney Int. 87, 909–917 (2015).
Huang, H. et al. Gentamicin-induced acute kidney injury in an animal model involves programmed necrosis of the collecting duct. J. Am. Soc. Nephrol. 31, 2097–2115 (2020).
Xu, Y. et al. A role for tubular necroptosis in cisplatin-induced AKI. J. Am. Soc. Nephrol. 26, 2647–2658 (2015).
Serio, A. W., Keepers, T., Andrews, L. & Krause, K. M. Aminoglycoside revival: review of a historically important class of antimicrobials undergoing rejuvenation. EcoSal https://doi.org/10.1128/ecosalplus.ESP-0002-2018 (2018).
Friedmann Angeli, J. P. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16, 1180–1191 (2014).
Manohar, S. & Leung, N. Cisplatin nephrotoxicity: a review of the literature. J. Nephrol. 31, 15–25 (2018).
Brady, H. R. et al. Mitochondrial injury: an early event in cisplatin toxicity to renal proximal tubules. Am. J. Physiol. 258, F1181–F1187 (1990).
Lieberthal, W., Triaca, V. & Levine, J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am. J. Physiol. 270, F700–F708 (1996).
Wang, J. N. et al. RIPK1 inhibitor Cpd-71 attenuates renal dysfunction in cisplatin-treated mice via attenuating necroptosis, inflammation and oxidative stress. Clin. Sci. 133, 1609–1627 (2019).
Rui, C. et al. The multitargeted kinase inhibitor KW-2449 ameliorates cisplatin-induced nephrotoxicity by targeting RIPK1-mediated necroptosis. Biochem. Pharmacol. 188, 114542 (2021).
Fennell, D. A. et al. Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat. Rev. 44, 42–50 (2016).
Landau, S. I. et al. Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease. Kidney Int. 95, 797–814 (2019).
Jha, V. et al. Chronic kidney disease: global dimension and perspectives. Lancet 382, 260–272 (2013).
Coresh, J. Update on the burden of CKD. J. Am. Soc. Nephrol. 28, 1020–1022 (2017).
Chen, Q. et al. 24-LB: RIPK1 activation induces necroptosis, proinflammation, and profibrosis in kidney of STZ/HFD-induced diabetic mice. Diabetes 69, 24-LB (2020).
Shi, Y. et al. RIPK3 blockade attenuates tubulointerstitial fibrosis in a mouse model of diabetic nephropathy. Sci. Rep. 10, 10458 (2020).
Xu, Y. et al. High glucose-induced apoptosis and necroptosis in podocytes is regulated by UCHL1 via RIPK1/RIPK3 pathway. Exp. Cell Res. 382, 111463 (2019).
Ma, T. et al. Excessive activation of Notch signaling in macrophages promote kidney inflammation, fibrosis, and necroptosis. Front. Immunol. 13, 835879 (2022).
Hildebrand, J. M. et al. A family harboring an MLKL loss of function variant implicates impaired necroptosis in diabetes. Cell Death Dis. 12, 345 (2021).
Hapca, S. et al. The relationship between AKI and CKD in patients with type 2 diabetes: an observational cohort study. J. Am. Soc. Nephrol. 32, 138–150 (2021).
McCaig, W. D. et al. Hyperglycemia potentiates a shift from apoptosis to RIP1-dependent necroptosis. Cell Death Discov. 4, 55 (2018).
LaRocca, T. J. et al. Hyperglycemic conditions prime cells for RIP1-dependent necroptosis. J. Biol. Chem. 291, 13753–13761 (2016).
Deragon, M. A. et al. Mitochondrial ROS prime the hyperglycemic shift from apoptosis to necroptosis. Cell Death Discov. 6, 132 (2020).
Oezkur, M. et al. Chronic hyperglycemia is associated with acute kidney injury in patients undergoing CABG surgery — a cohort study. BMC Cardiovasc. Disord. 15, 41 (2015).
Mendez, C. E., Der Mesropian, P. J., Mathew, R. O. & Slawski, B. Hyperglycemia and acute kidney injury during the perioperative period. Curr. Diab. Rep. 16, 10 (2016).
Gorelik, Y. et al. Hyperglycemia on admission predicts acute kidney failure and renal functional recovery among inpatients. J. Clin. Med. 11, 54 (2021).
Safian, R. D. & Textor, S. C. Renal-artery stenosis. N. Engl. J. Med. 344, 431–442 (2001).
Gansevoort, R. T. et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382, 339–352 (2013).
Karunakaran, D. et al. Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis. Sci. Adv. 2, e1600224 (2016).
Rasheed, A. et al. Loss of MLKL (mixed lineage kinase domain-like protein) decreases necrotic core but increases macrophage lipid accumulation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 40, 1155–1167 (2020).
Karunakaran, D. et al. RIPK1 expression associates with inflammation in early atherosclerosis in humans and can be therapeutically silenced to reduce NF-κB activation and atherogenesis in mice. Circulation 143, 163–177 (2021).
Puylaert, P. et al. The impact of RIPK1 kinase inhibition on atherogenesis: a genetic and a pharmacological approach. Biomedicines 10, 1016 (2022).
Colijn, S. et al. Cell-specific and athero-protective roles for RIPK3 in a murine model of atherosclerosis. Dis. Model. Mech. 13, dmm041962 (2020).
Anders, H. J. et al. Lupus nephritis. Nat. Rev. Dis. Prim. 6, 7 (2020).
Fan, H. et al. Activation-induced necroptosis contributes to B-cell lymphopenia in active systemic lupus erythematosus. Cell Death Dis. 5, e1416 (2014).
Sarhan, J. et al. Constitutive interferon signaling maintains critical threshold of MLKL expression to license necroptosis. Cell Death Differ. 26, 332–347 (2019).
Guo, C. et al. Pathogenesis of lupus nephritis: RIP3 dependent necroptosis and NLRP3 inflammasome activation. J. Autoimmun. 103, 102286 (2019).
Kitching, A. R. et al. ANCA-associated vasculitis. Nat. Rev. Dis. Prim. 6, 71 (2020).
Kessenbrock, K. et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 15, 623–625 (2009).
Muraro, S. P. et al. Respiratory syncytial virus induces the classical ROS-dependent NETosis through PAD-4 and necroptosis pathways activation. Sci. Rep. 8, 14166 (2018).
Sollberger, G. et al. Gasdermin D plays a vital role in the generation of neutrophil extracellular traps. Sci. Immunol. 3, eaar6689 (2018).
Silva, C. M. S. et al. Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation. Blood 138, 2702–2713 (2021).
Su, M. et al. Gasdermin D-dependent platelet pyroptosis exacerbates NET formation and inflammation in severe sepsis. Nat. Cardiovasc. Res. 1, 732–747 (2022).
Schreiber, A. et al. Necroptosis controls NET generation and mediates complement activation, endothelial damage, and autoimmune vasculitis. Proc. Natl Acad. Sci. USA 114, E9618–E9625 (2017).
Torra, R., Furlano, M., Ortiz, A. & Ars, E. Genetic kidney diseases as an underrecognized cause of chronic kidney disease: the key role of international registry reports. Clin. Kidney J. 14, 1879–1885 (2021).
Chapman, A. B. et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 88, 17–27 (2015).
Bergmann, C. et al. Polycystic kidney disease. Nat. Rev. Dis. Prim. 4, 50 (2018).
Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407–2418 (2012).
Yang, B. et al. Interleukin-1 receptor activation aggravates autosomal dominant polycystic kidney disease by modulating regulated necrosis. Am. J. Physiol. Renal Physiol. 317, F221–F228 (2019).
Li, X. et al. A tumor necrosis factor-α-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat. Med. 14, 863–868 (2008).
Dodson, J. L. et al. Urological disorders in chronic kidney disease in children cohort: clinical characteristics and estimation of glomerular filtration rate. J. Urol. 186, 1460–1466 (2011).
Meng, X. M., Nikolic-Paterson, D. J. & Lan, H. Y. Inflammatory processes in renal fibrosis. Nat. Rev. Nephrol. 10, 493–503 (2014).
Imamura, M. et al. RIPK3 promotes kidney fibrosis via AKT-dependent ATP citrate lyase. J. Clin. Invest. Insight 3, e94979 (2018).
Xiao, X. et al. Inhibition of necroptosis attenuates kidney inflammation and interstitial fibrosis induced by unilateral ureteral obstruction. Am. J. Nephrol. 46, 131–138 (2017).
Popper, B. et al. Neonatal obstructive nephropathy induces necroptosis and necroinflammation. Sci. Rep. 9, 18600 (2019).
Tonelli, M. et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am. J. Transpl. 11, 2093–2109 (2011).
Hariharan, S., Israni, A. K. & Danovitch, G. Long-term survival after kidney transplantation. N. Engl. J. Med. 385, 729–743 (2021).
Wu, W. K., Famure, O., Li, Y. & Kim, S. J. Delayed graft function and the risk of acute rejection in the modern era of kidney transplantation. Kidney Int. 88, 851–858 (2015).
Lau, A. et al. RIPK3-mediated necroptosis promotes donor kidney inflammatory injury and reduces allograft survival. Am. J. Transpl. 13, 2805–2818 (2013).
Pavlosky, A. et al. RIPK3-mediated necroptosis regulates cardiac allograft rejection. Am. J. Transpl. 14, 1778–1790 (2014).
Zhao, J. et al. Toll-like receptor 3 is an endogenous sensor of cell death and a potential target for induction of long-term cardiac transplant survival. Am. J. Transplant. 21, 3268–3279 (2021).
Kwok, C. et al. Necroptosis is involved in CD4+ T cell-mediated microvascular endothelial cell death and chronic cardiac allograft rejection. Transplantation 101, 2026–2037 (2017).
Aljabri, A. et al. HLA class II antibodies induce necrotic cell death in human endothelial cells via a lysosomal membrane permeabilization-mediated pathway. Cell Death Dis. 10, 235 (2019).
Gill, J. et al. Pulsatile perfusion reduces the risk of delayed graft function in deceased donor kidney transplants, irrespective of donor type and cold ischemic time. Transplantation 97, 668–674 (2014).
Helanterä, I., Ibrahim, H. N., Lempinen, M. & Finne, P. Donor age, cold ischemia time, and delayed graft function. Clin. J. Am. Soc. Nephrol. 15, 813–821 (2020).
Agrawal, A., Ison, M. G. & Danziger-Isakov, L. Long-term infectious complications of kidney transplantation. Clin. J. Am. Soc. Nephrol. 17, 286–295 (2022).
Santos, C. A., Brennan, D. C., Fraser, V. J. & Olsen, M. A. Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation. Transplantation 98, 187–194 (2014).
Blazquez-Navarro, A. et al. BKV, CMV, and EBV interactions and their effect on graft function one year post-renal transplantation: results from a large multi-centre study. EBioMedicine 34, 113–121 (2018).
Guo, H., Kaiser, W. J. & Mocarski, E. S. Manipulation of apoptosis and necroptosis signaling by herpesviruses. Med. Microbiol. Immunol. 204, 439–448 (2015).
Altman, A. M. et al. Human cytomegalovirus-induced autophagy prevents necroptosis of infected monocytes. J. Virol. 94, e01022-20 (2020).
Muscolino, E. et al. Species-specific inhibition of necroptosis by HCMV UL36. Viruses 13, 2134 (2021).
De Bosscher, K., Vanden Berghe, W. & Haegeman, G. The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 24, 488–522 (2003).
Gerber, A. N., Newton, R. & Sasse, S. K. Repression of transcription by the glucocorticoid receptor: a parsimonious model for the genomics era. J. Biol. Chem. 296, 100687 (2021).
Loupy, A. et al. The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am. J. Transplant. 20, 2318–2331 (2020).
Heutinck, K. M. et al. Viral double-stranded RNA sensors induce antiviral, pro-inflammatory, and pro-apoptotic responses in human renal tubular epithelial cells. Kidney Int. 82, 664–675 (2012).
Kaiser, W. J. et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J. Biol. Chem. 288, 31268–31279 (2013).
Duan, X. et al. Inhibition of keratinocyte necroptosis mediated by RIPK1/RIPK3/MLKL provides a protective effect against psoriatic inflammation. Cell Death Dis. 11, 134 (2020).
He, F. et al. Necrosulfonamide improves post-resuscitation myocardial dysfunction via inhibiting pyroptosis and necroptosis in a rat model of cardiac arrest. Eur. J. Pharmacol. 926, 175037 (2022).
Tummers, B. & Green, D. R. The evolution of regulated cell death pathways in animals and their evasion by pathogens. Physiol. Rev. 102, 411–454 (2022).
Schreibing, F. & Kramann, R. Mapping the human kidney using single-cell genomics. Nat. Rev. Nephrol. 18, 347–360 (2022).
Tanzer, M. C. et al. Quantitative and dynamic catalogs of proteins released during apoptotic and necroptotic cell death. Cell Rep. 30, 1260–1270.e1265 (2020).
Tanzer, M. C. et al. Phosphoproteome profiling uncovers a key role for CDKs in TNF signaling. Nat. Commun. 12, 6053 (2021).
Taylor, M. J., Lukowski, J. K. & Anderton, C. R. Spatially resolved mass spectrometry at the single cell: recent innovations in proteomics and metabolomics. J. Am. Soc. Mass. Spectrom. 32, 872–894 (2021).
Tanzer, M. C. A proteomic perspective on TNF-mediated signalling and cell death. Biochem. Soc. Trans. 50, 13–20 (2022).
Zhu, K. et al. Necroptosis promotes cell-autonomous activation of proinflammatory cytokine gene expression. Cell Death Dis. 9, 500 (2018).
Montalban-Bravo, G. et al. Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. Leukemia 34, 872–881 (2020).
Salem, F. et al. The spatially resolved transcriptional profile of acute T cell-mediated rejection in a kidney allograft. Kidney Int. 101, 131–136 (2022).
Gerhardt, L. M. S. & McMahon, A. P. Multi-omic approaches to acute kidney injury and repair. Curr. Opin. Biomed. Eng. 20, 100344 (2021).
Weisel, K. et al. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers. Pharmacol. Res. Perspect. 5, e00365 (2017).
Weisel, K. et al. Response to inhibition of receptor-interacting protein kinase 1 (RIPK1) in active plaque psoriasis: a randomized placebo-controlled study. Clin. Pharmacol. Ther. 108, 808–816 (2020).
Weisel, K. et al. A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis. BMJ Open Gastroenterol. 8, e000680 (2021).
Weisel, K. et al. A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis. Arthritis Res. Ther. 23, 85 (2021).
clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT05237284 (2022).
Vissers, M. et al. Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients. Clin. Transl. Sci. 15, 2010–2023 (2022).
Vandenabeele, P., Grootjans, S., Callewaert, N. & Takahashi, N. Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease models. Cell Death Differ. 20, 185–187 (2013).
Acknowledgements
The authors’ work is funded by a grant from Dr. Werner Jackstädt-Stiftung (to S.K.). S.K. is also supported by the infrastructure of the DFG Cluster of Excellence 2167 Precision Medicine in Chronic Inflammation. J.M.M. gratefully acknowledges support from the National Health and Medical Research Council of Australia (1172929, 9000719) and the Victorian State Government Operational Infrastructure Support Scheme.
Author information
Authors and Affiliations
Contributions
All authors researched data for this article, wrote the text and made substantial contributions to discussions on the content. All authors edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
J.M.M. has contributed to the development of necroptosis inhibitors in collaboration with Anaxis Pty Ltd. The other authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Nephrology thanks X.-M. Meng and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kolbrink, B., von Samson-Himmelstjerna, F.A., Murphy, J.M. et al. Role of necroptosis in kidney health and disease. Nat Rev Nephrol 19, 300–314 (2023). https://doi.org/10.1038/s41581-022-00658-w
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-022-00658-w
This article is cited by
-
The emerging role of regulated cell death in ischemia and reperfusion-induced acute kidney injury: current evidence and future perspectives
Cell Death Discovery (2024)
-
Mediators of necroptosis: from cell death to metabolic regulation
EMBO Molecular Medicine (2024)
-
Regulated cell death pathways in kidney disease
Nature Reviews Nephrology (2023)
-
Metformin potentiates nephrotoxicity by promoting NETosis in response to renal ferroptosis
Cell Discovery (2023)
